<DOC>
	<DOCNO>NCT00904839</DOCNO>
	<brief_summary>The primary objective study evaluate PFS rate 9 month BIBF 1120 combination mFolfox6 compare mFolfox6 combine bevacizumab first line patient metastatic colorectal cancer .</brief_summary>
	<brief_title>BIBF 1120 Versus Bevacizumab Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<criteria>Inclusion criterion : 1 . Age &gt; = 18 year 2 . Histologically proven colorectal adenocarcinoma 3 . No previous oxaliplatin base chemotherapy allow unless disease free survival end chemotherapy &gt; = 12 month 4 . No previous therapy VEGFR EGFR inhibitor 5 . No prior systemic therapy metastatic CRC 6 . No previous adjuvant therapy fluoropyrimidines allow unless disease free survival end chemotherapy &gt; 6 month 7 . ECOG performance status &lt; = 2 8 . Adequate hepatic , renal bone marrow function : 9 . No uncontrolled hypertension 10 . Signed date write informed consent prior admission study Exclusion criterion : 1 . Treatment investigational drug within 28 day trial onset . 2 . History malignancy last 5 year , particular could affect compliance protocol interpretation result . 3 . Serious concomitant disease , especially affect compliance trial requirement consider relevant evaluation efficacy safety trial drug , 4 . Major injury and/or surgery bone fracture within 4 week trial inclusion , plan surgical procedure trial period . 5 . Significant cardiovascular disease 6 . History severe haemorrhagic thromboembolic event past 12 month . Known inherited predisposition bleed thrombosis . 7 . Patient brain metastasis symptomatic and/or require therapy . 8 . Pregnancy breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>